Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ
News
Market Data
Register to chat with like-minded investors on our interactive forums.
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 14.64M | 62.18M |
| Operating Income | -85.3M | -78.34M | -86.45M | -98.53M | -117.18M | -152.04M | -162.54M | -116.3M |
| Pre Tax Income | -85.91M | -76.9M | -85.8M | -98.74M | -112.19M | -147.54M | -151.97M | -106.96M |
| Net Income | -85.91M | -76.9M | -85.8M | -98.74M | -112.19M | -147.54M | -151.97M | -106.96M |
| Preferred Dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic Earnings Per Share (EPS) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | -85.3M | -78.34M | -86.45M | -98.53M | -117.18M | -152.04M | -162.54M | -116.3M |
| EBITDA | -85.17M | -78.21M | -86.32M | -98.4M | -117.03M | -151.87M | -162.27M | -116.01M |
| Year End December 30 2023 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -25.22M | -32.06M | -40.68M | -94.97M | -206.67M | -242.48M | -293.57M | -380.5M |
| Pre Tax Income | -26.39M | -31.15M | -32.81M | -83.95M | -202.24M | -241.85M | -295.35M | -373.63M |
| Net Income | -26.39M | -31.15M | -32.81M | -83.95M | -202.24M | -241.85M | -295.35M | -373.63M |
| Preferred Dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic Earnings Per Share (EPS) | -2.208 | -1.923 | -1.888 | -4.825 | -11.571 | -12.68 | -14.714 | -17.208 |
| EBIT | -25.22M | -31.71M | -40.48M | -94.97M | -206.57M | -242.21M | -293.57M | -380.5M |
| EBITDA | -25.22M | -31.99M | -40.59M | -94.86M | -206.2M | -242.08M | -293.1M | -379.97M |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
